Pharvaris (PHVS) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Pharvaris
Is Pharvaris a buy right now? The alternative data leans yes. This PHVS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Pharvaris every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 60/100: a Buy. The stock trades at $40.21 with a $3B market cap.
What’s driving the buy signal over the past 90 days: job postings up 153.3% to 38 open roles, web traffic up 37.8% to 8K monthly visits, and headcount (according to LinkedIn) up 7.2% to 164 employees. Stocks scoring above 60 have historically outperformed the S&P 500 over the following six months.
PHVS’s broader alt-data profile also covers X followers (74), and sentiment (100/100). Every signal links to its own page with full history, the PHVS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on PHVS is just below.
Pharvaris AI Stock Analysis
Pharvaris is a biopharmaceutical company focused on developing oral bradykinin B2-receptor antagonists to treat hereditary angioedema and other bradykinin-mediated diseases. With a robust product pipeline, the company aims to address unmet medical needs through innovative therapeutic solutions.
Analysis generated September 1, 2026.
Recent Pharvaris Stock Alerts
|
Pharvaris | September 11 Price is up by 6.7% in the last 24h. |
|
Pharvaris | September 8 Price is up by 17.3% in the last 24h. |
|
Pharvaris | August 13 Price is down by -6.1% in the last 24h. |
|
Pharvaris | August 6 Price is up by 6.2% in the last 24h. |
Pharvaris Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 8K | 37.8% | |
| Job Posts | 38 | 153.3% | |
| LinkedIn Employees | 164 | 7.2% | |
| Sentiment | 100 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 2 | 33.3% | |
| Stocktwits Mentions | 41 | 4,000.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 1K | 14.8% | |
| X Followers | 74 | 17.5% | |
| Facebook Followers | 24 | 9.1% | |
| Facebook Engagement | 0 | N/A |
About Pharvaris (PHVS)
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the Netherlands.
| Price | $40.21 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $3B |
| Year Range | $21 – $38 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Pharvaris News
View more →
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema AttacksJuly 6 - GlobeNewswire |
|
Pharvaris Announces Annual General Meeting of ShareholdersJune 11 - GlobeNewswire |
|
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026May 29 - GlobeNewswire |
|
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 11 - GlobeNewswire |
|
 |
The 'Blowout' And 'Bull Case' News That Sent Two Biotechs FlyingSeptember 8 - Biztoc.com |
See Pharvaris’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for PHVS, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEPharvaris Earnings & Financial Performance
View all earnings →Pharvaris Insider Trading Activity
View all →| Modig Berndt filed to sell 132,917 shares at $0.0. Jul 13 '26 |
| Lesage Anne filed to sell 58,750 shares at $0.0. Jun 30 '26 |
| Lesage Anne filed to sell 93,969 shares at $0.0. Jun 30 '26 |
| Schikan Johannes Gerardus Christiaan Petrus filed to sell 315,167 shares at $0.0. Jun 30 '26 |
| Lesage Anne filed to sell 56,450 shares at $0.0. Jun 29 '26 |
Pharvaris Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Pharvaris
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
AtaiBeckleyATAI |
$7.35 0.8% | $3B | 66 |
 |
Nurix TherapeuticsNRIX |
$25.10 2.8% | $3B | 56 |
 |
Structure TherapeuticsGPCR |
$38.66 2.3% | $3B | 48 |
 |
Soleno TherapeuticsSLNO |
$53.01 0.0% | $3B | 56 |
 |
ImmunomeIMNM |
$25.53 2.2% | $3B | 47 |
Explore Pharvaris Data
Frequently Asked Questions: Pharvaris (PHVS)
Pharvaris has an AltIndex AI Score of 60/100 (Buy). The score reflects positive alternative data signals. All investments carry risk.
60/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Pharvaris (PHVS) stock is $40.21 with a market cap of $3B.
As of today, Pharvaris’s PE (Price to Earnings) ratio is —.
View the latest Pharvaris insider transactions to see recent buying and selling activity by company executives and directors.
Check the Pharvaris congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The PHVS stock price chart above shows Pharvaris’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Pharvaris technical analysis for RSI, moving averages, and more.
See the stocks similar to Pharvaris section on this page for companies in the same industry ranked by market cap and AI Score.
